Israeli biotech 89Bio has just raised $60 million to advance its pipeline of biologic and small molecule treatments for liver and metabolic disorders. 89Bio’s BIO89-100 is in a phase 1 clinical trial for treating nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease.
https://www.calcalistech.com/ctech/articles/0,7340,L-3748585,00.html